Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the ...

Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion. Analysts surveyed by Visible Alpha were looking for $4.19 and $2.83 billion, ...

Janice Chen co-founded Mammoth Biosciences after inventing a powerful gene detection tool in grad school. Now she's helping ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

The stock's fall snapped a four-day winning streak.

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 15 years ago, it would be worth $1,256.99 today based on a ...